Xxiv международная медико-биологическая конференция молодых исследователей Фундаментальная наука и клиническая

Conclusion: 
The aim of this abstract was to give an overview of 
possible mechanisms that can lead to CFS and to provide some of potential 
treatments that could bring us closer to the real matter. Cognitive-
behavior, re-co-conditioning and pharmacological therapy could be 
used. High-frequency repetitive trnscranial magnetic stimulation (rTMS) 
applied over the dorsolateral prefrontal cortex (DLPFC) showed some 
promising results. Presumably, it works via increasing the neural activity 
in that area, which decreases fatigue symptoms. Next experimental drug 
is oral pyridostigmine which is found to increase response to nerve 
stimulation and muscle strength. Also, of those 3 patients that were given 
a pyridostigmine, 2 were relieved of their symptoms and the third one 
was showing improvement of fatigability. Because of unrefreshing sleep, 
function of melatonin was explored. Even though some studies showed 
that melatonin level were similar (or even higher) in CFS patients and 
healthy (CFS=86 pg/mL, healthy=76 pg/mL, [p<0,005]), other studies 
showed improved symptoms after melatonin administrations. Results after 
melatonin administration showed improved quality of life in CFS patients 
who had late melatonin onset before treatment. This was measured by the 
checklist individual strength — CIS score. Higher results indicate most 
severe clinical symptoms (MAX= 150). Control group had mean CIS 
score 47,3 and CFS patients 111,0. After several weeks of administration 
of 5 mg melatonin, CFS patients' CIS score was 92,4 [p< 0,006].

---

944
V САТЕЛЛИТНЫЙ СИМПОЗИУМ ПО КЛИНИЧЕСКОЙ ПАТОФИЗИОЛОГИИ
ИНТЕРФЕРЕНЦИЯ ПУРИНЕРГИЧЕСКИХ СИГНАЛОВ 
КАК ФАКТОР ВИРУЛЕНТНОСТИ MYCOBACTERIUM 
TUBERCULOSIS ДЛЯ УКЛОНЕНИЯ ОТ ИММУННЫХ 
ОТВЕТОВ